United States· US:70771-1015_58be95eb-5701-463e-b80c-eb9b6c2a789d
Nateglinide
A nateglinide product containing nateglinide, registered in United States by Zydus Lifesciences Limited. The same ATC class is registered in 5 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Nateglinide is registered in 5 of 19 countries.
Countries holding a registration under ATC A10BX03 (nateglinide), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 3 of them publish a price we can compare per daily dose
Nateglinide · ATC A10BX03
5 / 19 countries
- Belgiumprice
- Finlandprice
- Japan
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- NATEGLINIDE
- Manufacturer
- Zydus Lifesciences Limited
- Country
- United States (US)
- ATC code
- A10BX03
- ATC class
- Nateglinide
- Defined daily dose
- 0.36 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 12
- ndc1170771101501000 TABLET, FILM COATED in 1 BOTTLE (70771-1015-0)
- ndc117077110151100 TABLET, FILM COATED in 1 BOTTLE (70771-1015-1)
- ndc11707711015330 TABLET, FILM COATED in 1 BOTTLE (70771-1015-3)
- ndc11707711015410 BLISTER PACK in 1 CARTON (70771-1015-4) / 10 TABLET, FILM COATED in 1 BLISTER PACK (70771-1015-2)
- ndc117077110155500 TABLET, FILM COATED in 1 BOTTLE (70771-1015-5)
- ndc11707711015990 TABLET, FILM COATED in 1 BOTTLE (70771-1015-9)
- ndc1170771-1015-0
- ndc1170771-1015-1
- ndc1170771-1015-3
- ndc1170771-1015-4
- ndc1170771-1015-5
- ndc1170771-1015-9
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
626 interactions on record for nateglinide.
Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Nateglinide · interactions on record
626 records
- 15 severe
- 429 moderate
- 45 minor
- 137 info
Most severe, free to view
- SucralfateA02BX02moderate
- ThiethylperazinA04AB03moderate
- TriflupromazinA04AD06moderate
- AprepitantA04AD12moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Nateglinide in 4 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e116a365-bc39-4f24-8469-3265df59ab69 GET /v1/drugs/e116a365-bc39-4f24-8469-3265df59ab69?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "60",
"substance": "NATEGLINIDE",
"productndc": "70771-1015",
"dosage_form": "TABLET, FILM COATED",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "ANDA205248",
"marketing_category": "ANDA"
}See everything about nateglinide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.